OraSure Technologies (NASDAQ:OSUR) Stock Rating Upgraded by Wall Street Zen

OraSure Technologies (NASDAQ:OSUR) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings raised shares of OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $3.00.

OraSure Technologies Stock Performance

OSUR opened at $3.97 on Friday. The firm has a market cap of $273.33 million, a P/E ratio of -3.82 and a beta of 1.01. The business has a 50 day moving average price of $4.08 and a 200 day moving average price of $3.33. OraSure Technologies has a twelve month low of $2.08 and a twelve month high of $4.58.

Insiders Place Their Bets

In other OraSure Technologies news, Director Steven Kyle Boyd bought 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The stock was purchased at an average price of $2.99 per share, for a total transaction of $74,750.00. Following the purchase, the director directly owned 113,462 shares in the company, valued at $339,251.38. This trade represents a 28.26% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Peapod Lane Capital LLC boosted its position in shares of OraSure Technologies by 51.1% in the fourth quarter. Peapod Lane Capital LLC now owns 1,018,470 shares of the medical instruments supplier’s stock valued at $2,465,000 after acquiring an additional 344,437 shares during the period. Tudor Investment Corp ET AL bought a new position in OraSure Technologies during the third quarter worth $808,000. Yorkville Advisors Global LP bought a new position in OraSure Technologies during the first quarter worth $1,905,000. Envestnet Asset Management Inc. raised its stake in OraSure Technologies by 32.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 8,133 shares during the last quarter. Finally, Jain Global LLC acquired a new position in OraSure Technologies during the 4th quarter valued at $76,000. 93.50% of the stock is currently owned by institutional investors and hedge funds.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.